Hollsteen
← Jabil

Research and development

Flow – sum over the period · $M

QuartersFiscal years

$MResearch and development · Q1 FY2016: $8.0M · 10-Q 0001193125-16-422561 filed Jan 6, 2016Research and development · Q2 FY2016: $8.0M · 10-Q 0001193125-16-530833 filed Apr 5, 2016Research and development · Q3 FY2016: $8.0M · 10-Q 0001193125-16-638261 filed Jun 30, 2016Research and development · Q4 FY2016: $8.0M · derived · 10-K 0001193125-17-313834 filed Oct 19, 2017Research and development · Q1 FY2017: $8.0M · 10-Q 0001193125-17-005745 filed Jan 9, 2017Research and development · Q2 FY2017: $7.0M · 10-Q 0001193125-17-111778 filed Apr 5, 2017Research and development · Q3 FY2017: $7.0M · 10-Q 0001193125-17-219901 filed Jun 30, 2017Research and development · Q4 FY2017: $8.0M · derived · 10-K 0001193125-18-303041 filed Oct 19, 2018Research and development · Q1 FY2018: $9.0M · 10-Q 0001193125-18-002956 filed Jan 4, 2018Research and development · Q2 FY2018: $8.0M · 10-Q 0001193125-18-108777 filed Apr 5, 2018Research and development · Q3 FY2018: $10.0M · 10-Q 0001193125-18-207639 filed Jun 28, 2018Research and development · Q4 FY2018: $11.0M · derived · 10-K 0001193125-19-271646 filed Oct 22, 2019Research and development · Q1 FY2019: $11.0M · 10-Q 0001193125-19-005404 filed Jan 9, 2019Research and development · Q2 FY2019: $10.0M · 10-Q 0001193125-19-097892 filed Apr 4, 2019Research and development · Q3 FY2019: $11.0M · 10-Q 0001193125-19-186025 filed Jun 28, 2019Research and development · Q4 FY2019: $10.0M · derived · 10-K 0001193125-20-274411 filed Oct 22, 2020Research and development · Q1 FY2020: $11.0M · 10-Q 0001193125-20-001434 filed Jan 3, 2020Research and development · Q2 FY2020: $11.0M · 10-Q 0001193125-20-094625 filed Apr 1, 2020Research and development · Q3 FY2020: $12.0M · 10-Q 0001193125-20-183269 filed Jun 29, 2020Research and development · Q4 FY2020: $9.0M · derived · 10-K 0001193125-21-305429 filed Oct 22, 2021Research and development · Q1 FY2021: $8.0M · 10-Q 0001193125-21-004678 filed Jan 8, 2021Research and development · Q2 FY2021: $9.0M · 10-Q 0001193125-21-104662 filed Apr 2, 2021Research and development · Q3 FY2021: $10.0M · 10-Q 0001193125-21-207682 filed Jul 2, 2021Research and development · Q4 FY2021: $7.0M · derived · 10-K 0001193125-22-268383 filed Oct 25, 2022Research and development · Q1 FY2022: $9.0M · 10-Q 0001193125-22-004029 filed Jan 7, 2022Research and development · Q2 FY2022: $8.0M · 10-Q 0001193125-22-092806 filed Apr 1, 2022Research and development · Q3 FY2022: $8.0M · 10-Q 0001193125-22-186715 filed Jul 1, 2022Research and development · Q4 FY2022: $8.0M · derived · 10-K 0001193125-23-259599 filed Oct 20, 2023Research and development · Q1 FY2023: $9.0M · 10-Q 0001193125-23-003543 filed Jan 6, 2023Research and development · Q2 FY2023: $8.0M · 10-Q 0001193125-23-091542 filed Apr 5, 2023Research and development · Q3 FY2023: $8.0M · 10-Q 0001193125-23-179422 filed Jun 30, 2023Research and development · Q4 FY2023: $9.0M · derived · 10-K 0001628280-24-043960 filed Oct 28, 2024Research and development · Q1 FY2024: $10.0M · 10-Q 0001193125-24-004852 filed Jan 9, 2024Research and development · Q2 FY2024: $10.0M · 10-Q 0001628280-24-014951 filed Apr 5, 2024Research and development · Q3 FY2024: $9.0M · 10-Q 0001628280-24-031429 filed Jul 9, 2024Research and development · Q4 FY2024: $10.0M · derived · 10-K 0001628280-25-045293 filed Oct 17, 2025Research and development · Q1 FY2025: $8.0M · 10-Q 0001628280-25-001058 filed Jan 10, 2025Research and development · Q2 FY2025: $7.0M · 10-Q 0001628280-25-017004 filed Apr 8, 2025Research and development · Q3 FY2025: $7.0M · 10-Q 0001628280-25-033410 filed Jun 30, 2025Research and development · Q4 FY2025: $4.0M · derived · 10-K 0001628280-25-045293 filed Oct 17, 2025Research and development · Q1 FY2026: $7.0M · 10-Q 0001628280-26-001450 filed Jan 9, 2026Research and development · Q2 FY2026: $7.0M · 10-Q 0001628280-26-024148 filed Apr 8, 2026Research and development · Q3 FY2026: $9.0M · 10-Q 0001628280-26-046138 filed Jun 30, 20268.09.08.311.6Q1 FY2016Q3 FY2026Q2 FY2022
$MResearch and development · Q2 FY2021: $9.0M · 10-Q 0001193125-21-104662 filed Apr 2, 2021Research and development · Q3 FY2021: $10.0M · 10-Q 0001193125-21-207682 filed Jul 2, 2021Research and development · Q4 FY2021: $7.0M · derived · 10-K 0001193125-22-268383 filed Oct 25, 2022Research and development · Q1 FY2022: $9.0M · 10-Q 0001193125-22-004029 filed Jan 7, 2022Research and development · Q2 FY2022: $8.0M · 10-Q 0001193125-22-092806 filed Apr 1, 2022Research and development · Q3 FY2022: $8.0M · 10-Q 0001193125-22-186715 filed Jul 1, 2022Research and development · Q4 FY2022: $8.0M · derived · 10-K 0001193125-23-259599 filed Oct 20, 2023Research and development · Q1 FY2023: $9.0M · 10-Q 0001193125-23-003543 filed Jan 6, 20238.09.09.49.7Q2 FY2021Q1 FY2023Q2 FY2022
Q2 FY2022
8.0$M
All values (43)
PeriodValue ($M)Status
Q3 FY20269.0reported
Q2 FY20267.0reported
Q1 FY20267.0reported
Q4 FY20254.0derived
Q3 FY20257.0reported
Q2 FY20257.0reported
Q1 FY20258.0reported
Q4 FY202410.0derived
Q3 FY20249.0reported
Q2 FY202410.0reported
Q1 FY202410.0reported
Q4 FY20239.0derived
Q3 FY20238.0reported
Q2 FY20238.0reported
Q1 FY20239.0reported
Q4 FY20228.0derived
Q3 FY20228.0reported
Q2 FY20228.0reported
Q1 FY20229.0reported
Q4 FY20217.0derived
Q3 FY20219.7reported
Q2 FY20219.4reported
Q1 FY20218.1reported
Q4 FY20209.4derived
Q3 FY202011.6reported
Q2 FY202011.3reported
Q1 FY202010.8reported
Q4 FY201910.1derived
Q3 FY201911.4reported
Q2 FY201910.2reported
Q1 FY201911.1reported
Q4 FY201811.0derived
Q3 FY201810.1reported
Q2 FY20188.3reported
Q1 FY20189.1reported
Q4 FY20177.7derived
Q3 FY20177.3reported
Q2 FY20177.1reported
Q1 FY20177.6reported
Q4 FY20167.5derived
Q3 FY20167.7reported
Q2 FY20168.5reported
Q1 FY20168.3reported

CSV with all sources · Technical ID: rnd

More metrics for Jabil

Income statement

Per share

Balance sheet

Cash flow

Debt and interest

Revenue by segment/product/region

Operating income by segment

Sources & calculation
Value
$8.0M
Period
Q2 FY2022, ended Feb 28, 2022 · quarterly value (3 months, not cumulative)
Source
10-Q, filed Apr 1, 2022 · 0001193125-22-092806
Location
us-gaap:ResearchAndDevelopmentExpense
Confidence
1. – directly from an XBRL fact in the filing (or calculated exactly from it)

Versions

v1$8.0MApr 1, 202210-Q 0001193125-22-092806reported · confidence 1. · current